Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cladribine + Cytarabine + Tagraxofusp-erzs |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cladribine | Leustatin | 2-CdA | Leustatin (cladribine) is a purine analog that is incorporated into DNA, resulting in DNA single strand breaks and apoptosis (NCI Drug Dictionary). | |
Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). | |
Tagraxofusp-erzs | Elzonris | Tagraxofusp|SL-401|DT3881L3|DT-3881L3 | Elzonris (Tagraxofusp-erzs) is a fusion protein consists of human interleukin 3 (IL3) and the first 388 amino acids of diphtheria toxin [DT(388)], which binds to IL3 receptors and subsequently inhibits protein synthesis, leading to cell death (PMID: 28479592). Elzonris (tagraxofusp-erzs) is FDA approved for use in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06561152 | Phase Ib/II | Cladribine + Cytarabine + Tagraxofusp-erzs | Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML | Not yet recruiting | USA | 0 |